Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this clinical trial is to learn about Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the treatment of second-line and above failure MSS(microsatellite stability) metastatic colorectal cancer. The main question it aims to answer is: The efficacy and safety of Fruquintinib combined with Adebrelimab and high and low dose radiotherapy in the third line and beyond treatment of MSS metastatic colorectal cancer. Participants will receive the combination of Fruquintinib and Adebrelimab within 3 weeks after completion of high and low dose radiotherapy on metastases until disease progression or intolerable toxicity occurred.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old, gender not limited； 2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1； 3. Previously identified as MSS type mCRC； 4. Metastatic colorectal cancer (mCRC) with disease progression after receiving standard second-line treatment according to Chinese Society of Clinical Oncology ( CSCO) guidelines； 5. At least one measurable lesion (RECIST 1.1)； 6. Be able to adhere to the protocol during the research period； 7. Sign the informed consent form. Exclusion Criteria: 1. For individuals with a history of uncontrolled epilepsy, central nervous system disorders, or mental disorders, the clinical severity of which may hinder the signing of informed consent forms or affect the patient's adherence to oral medication, as determined by the researcher； 2. Accompanied by other malignant tumors that have not been cured； 3. The baseline blood routine and biochemical indicators of the subject do not meet the following criteria: hemoglob